IP Library Granted Patent US 10,981,921
Granted Patent B2
US 10,981,921 · App. 16/985,096 · Granted Apr 20, 2021

Fragment synthesis of substituted cyclic peptides

Inventors: Manuel Perez Vazquez (Milton, CA); M. Monzur Morshed (Mississauga, CA); Jennifer L. Hickey (Toronto, CA); Marc-André Poupart (Laval, CA); Gaoqiang Yang (Montreal, CA); James Gillard (Rosemere, CA); Adam Paul Kafal (Toronto, CA); Andrew L. Roughton (Port Hope, CA)
Assignee: Zealand Pharma A/S
C07D487/04A61P1/04C07C271/18C07C271/22C07D207/16C07K1/1075C07K7/06C07K7/54C07K7/56C07K7/64A61K9/0014A61K9/0053A61K38/00C07C2603/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,981,921
App. No.
16/985,096
Granted
Apr 20, 2021
Kind
B2
Abstract

There is described herein use of a compound of formula (I) below to make cyclic peptides.

Claims (15)

1. A cyclic peptide of formula (II):

or a stereoisomer thereof,

wherein:

—C(O)-L-Z— is selected from the group consisting of:

2. The cyclic peptide of claim 1 , or a stereoisomer thereof, wherein —C(O)-L-Z— is:

3. The cyclic peptide of claim 2 , or a stereoisomer thereof, wherein the cyclic peptide, or stereoisomer thereof, is:

4. The cyclic peptide of claim 1 , or a stereoisomer thereof, wherein —C(O)-L-Z— is:

5. The cyclic peptide of claim 4 , or a stereoisomer thereof, wherein the cyclic peptide, or stereoisomer thereof, is selected from the group consisting of:

6. The cyclic peptide of claim 1 , or a stereoisomer thereof, wherein —C(O)-L-Z— is:

7. The cyclic peptide of claim 6 , or a stereoisomer thereof, wherein the cyclic peptide, or stereoisomer thereof, is:

8. The cyclic peptide of claim 1 , or a stereoisomer thereof, wherein —C(O)-L-Z— is:

9. The cyclic peptide of claim 8 , or a stereoisomer thereof, wherein the cyclic peptide, or stereoisomer thereof, is:

10. The cyclic peptide of claim 1 , or a stereoisomer thereof, wherein —C(O)-L-Z— is:

11. The cyclic peptide of claim 10 , or a stereoisomer thereof, wherein the cyclic peptide, or stereoisomer thereof, is:

12. A cyclic peptide, or a stereoisomer thereof, wherein the cyclic peptide, or stereoisomer thereof, is selected from the group consisting of:

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded May 17, 2023
From: ZOOLANDER SA LLC
To: ZEALAND PHARMA A/S
Reel/Frame 063672/0342 →
RELEASE OF SECURITY INTEREST Recorded May 11, 2023
From: ZOOLANDER SA LLC
To: ZEALAND PHARMA A/S
Reel/Frame 063624/0547 →
PATENT SECURITY AGREEMENT Recorded Dec 27, 2021
From: ZEALAND PHARMA A/S
To: ZOOLANDER SA LLC
Reel/Frame 058593/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2020
From: POUPART, MARC-ANDRÉ; YANG, GAOQIANG; GILLARD, JAMES
To: UNIVERSITE DE MONTREAL
Reel/Frame 054468/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2020
From: VAZQUEZ, MANUEL PEREZ; MORSHED, M. MONZUR; HICKEY, JENNIFER L.; KAFAL, ADAM PAUL; ROUGHTON, ANDREW L.
To: ENCYCLE THERAPEUTICS INC.
Reel/Frame 054468/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2020
From: ENCYCLE THERAPEUTICS INC.
To: ZEALAND PHARMA A/S
Reel/Frame 054468/0946 →